

April 28, 2016

President and Representative Director: Gyo Sagara
Code No: 4528 at the 1st section of the Tokyo Stock Exchange
INQUIRIES: Yukio Tani, Director, Corporate Communications
public_relations@ono.co.jp

Announcement on Candidates of Members of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers

ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President and Representative Director, Gyo Sagara; "ONO") announced that its Board of Directors meeting held on April 28, 2016 decided the candidates of Members of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers.

The candidates of Members of the Board of Directors and Audit & Supervisory Board Members will be submitted for approval to the 68th Annual Shareholders Meeting to be held late June 2016. The changes and appointments of Members of the Board of Directors and Corporate Officers will be resolved at the Board of Directors meeting to be held on the same day of the Annual Shareholders Meeting.

1. Changes of Members of the Board of Directors (as of late June 2016):
Incumbent Members of the Board of Directors and Corporate Officers will be re-appointed.
2. Changes of Audit & Supervisory Board Members (as of late June 2016):
- Katsuyoshi Nishimura will be re-appointed as a full-time Corporate Auditor.

2.1 New candidates of Audit & Supervisory Board Members

-Yasuo Hishiyama, Outside Audit & Supervisory Board Member (Lawyer: TANABE & PARTNERS)

Birth date: February 11, 1973

[Career]

April 1999 Appointed as a judicial nominee and joined at Sendai District Court

April 2001 Joined at Saitama District Court

April 2004 Joined at Osaka Domestic Relations Court

April 2006 Registered as lawyer, Daiichi Tokyo Bar Association

Joined at TANABE & PARTNERS

January 2010 Appointed as a member of appraisal committee at Tokyo District Court

2.2 Resigning Audit & Supervisory Board Members

- Narihito Maishi, Outside Audit & Supervisory Board Member

3. Changes of Corporate Officers (as of late June 2016):

Except for the following candidates of Corporate Officers, incumbent Corporate Officers will be re-appointed.

New candidates of Corporate Officer

- Yukio Tani, Corporate Officer, Director, Corporate Communications
- Toshihiro Tsujinaka, Corporate Officer, Business Unit Director, Oncology Business Unit, Sales and Marketing
- Hiromu Habashita, Corporate Officer, Executive Director, Discovery and Research

< Reference >

The followings are the appointments of Members of the Board of Directors, Audit & Supervisory Board Members as well as Corporate Officers (as of late June 2016).

*: Candidates of Members of the Board of Directors and Audit & Supervisory Board Members for subject to approval at the 68th Annual Shareholders Meeting

Members of the Board of Directors:

- Gyo Sagara, President, Representative Director, and Chief Executive Officer *
- Hiroshi Awata, Vice President Executive Officer, Executive Director, Clinical Development *
- Kei Sano, Senior Executive Officer, Executive Director, Corporate Management *
- Kazuhito Kawabata, Executive Officer, Executive Director, Corporate Regulatory Compliance Safety and Quality *
- Isao Ono, Executive Officer, Director, Corporate Research *
- Yutaka Kato, Outside Director *
- Jun Kurihara, Outside Director *

Audit & Supervisory Board Members:

- Katsuyoshi Nishimura, Audit & Supervisory Board Member *
- Shinji Fujiyoshi, Audit & Supervisory Board Member
- Hiromi Sakuhana, Outside Audit & Supervisory Board Member
- Yasuo Hishiyama, Outside Audit & Supervisory Board Member *

Corporate Officers:

- Shozo Matsuoka, Corporate Officer, Director, Medical Affairs
- Hiroshi Ichikawa, Corporate Officer/Senior Director, Metropolitan area management & Metropolitan area First Branch

- Toichi Takino, Corporate Officer, Executive Director, Corporate Development & Strategy
- Katsuji Teranishi, Corporate Officer/Director, Kyusyu-Okinawa Branch
- Noriyoshi Matsumoto, Corporate Officer, Executive Director, Sales and Marketing
- Takuya Seko, Corporate Officer, Executive Director, CMC Production & CMC Research
- Yukio Tani, Corporate Officer, Director, Corporate Communications
- Toshihiro Tsujinaka, Corporate Officer, Business Unit Director, Oncology Business Unit, Sales and Marketing
- Hiromu Habashita, Corporate Officer, Executive Director, Discovery and Research